Wearlinq

Wearlinq manufactures the eWave, a FDA-cleared 6-lead wireless cardiac monitoring system designed for mobile cardiac telemetry and extended Holter monitoring. The device is imperceptible, featuring skin-like electrodes and a 5-day battery life per charge, with continuous data transmission to a cloud platform. The eWave captures six distinct ECG leads wirelessly, eliminating traditional wires while delivering diagnostic-grade cardiac data. The company operates Wearlinq Labs, an IDTF (Independent Diagnostic Testing Facility) with 33 years of cardiology service experience, staffed by Certified Cardiographic Technicians providing 24/7 coverage. Wearlinq delivers high-quality cardiology reports within 2 days and produces STAT reports daily. The platform includes a mobile application enabling real-time access to EKG data, digital diary functionality to correlate symptoms with cardiac events, connectivity monitoring to ensure signal quality, and 24/7 patient concierge support. The company targets cardiology practices, outpatient facilities, and hospitals requiring remote cardiac monitoring capabilities. Wearlinq received FDA clearance for the eWave and recently raised $14 million in funding, indicating active development and market expansion in the cardiac monitoring sector.